Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

43P - Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial


31 Mar 2023


Poster Display session


Shengxiang Ren


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


S. Ren1, X. Wang2, B. Han3, Y. Pan4, J. Zhao5, Y. Cheng6, S. Hu7, T. Liu8, Y. Li9, Y. Cheng10, J. Feng11, S. Yi12, S. Gu13, S. Gao14, Y. Luo15, Y. Liu16, C. Liu17, H. Duan18, C. Zhou19, J. Fan20

Author affiliations

  • 1 Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai/CN
  • 2 the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou/CN
  • 3 Shanghai Chest Hospital, Shanghai/CN
  • 4 the First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei/CN
  • 5 Beijing Cancer Hospital, Beijing/CN
  • 6 Qilu Hospital of Shandong University, Jinan/CN
  • 7 Hubei Cancer Hospital, Wuhan/CN
  • 8 Zhongshan Hospital Affiliated to Fudan University, Shanghai/CN
  • 9 West China School of Medicine/West China Hospital of Sichuan University, Chengdu/CN
  • 10 Jilin Cancer Hospital, Changchun/CN
  • 11 Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing/CN
  • 12 Zhengzhou Central Hospital, Zhengzhou/CN
  • 13 Hunan Cancer Hospital, Changsha/CN
  • 14 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang/CN
  • 15 Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha/CN
  • 16 the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CN
  • 17 Shengjing Hospital of China Medical University, Shenyang/CN
  • 18 Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai/CN
  • 19 Shanghai Pulmonary Hospital and Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai/CN
  • 20 Zhongshan Hospital, Fudan University, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 43P


The combination of immune-checkpoint inhibitors and antiangiogenic agents can modulate the microenvironment in a synergistic manner and represents a promising treatment option for NSCLC. The efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) as first-line therapy for advanced NSCLC with PD-L1 TPS ≥1% was explored in an open-label, multicenter, phase II basket trial.


Eligible patients (pts) received camrelizumab (200 mg once every 3 weeks by intravenous infusion) plus oral famitinib (20 mg once daily). Primary endpoint was confirmed objective response rate (ORR) assessed by investigator per RECIST v1.1. Disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 6-, 9-, 12-month OS rates and safety profile were secondary endpoints.


Among all enrolled 41 pts, 21 (51.2%) had PD-L1 TPS 1–49% and 20 (48.8%) had PD-L1 TPS ≥50% per local laboratory testing. As of data cutoff on Jun 22, 2022, 22 (53.7%) pts had achieved a confirmed objective response. This combination regimen achieved an ORR of 53.7% (95% confidence interval [CI], 37.4–69.3), and the DCR was 92.7% (95% CI, 80.1–98.5). Median DoR had not been reached yet and the median TTR was 2.1 mos (range, 1.4–8.3). With the median follow-up duration of 12.5 mos (range, 1.0–24.2), the median PFS was 16.6 mos (95% CI, 8.3-NR), median OS was 20.4 mos (95% CI, 20.4-NR; data not mature), and the estimated 12-month OS rate was 76.8% (95% CI, 60.0–87.3), respectively. The most common ≥ grade 3 treatment-related adverse events were hypertension (22.0%), increased alanine aminotransferase (12.2%) and decreased neutrophil count (9.8%). One patient (2.4%) died from grade 5 hemoptysis, which the investigator considered possibly related to the study treatment.


Camrelizumab plus famitinib exhibited encouraging antitumor activity in advanced NSCLC pts whose tumor expressed PD-L1 TPS ≥1% with an acceptable safety profile. In this patient population, this combination regimen might offer an alternative treatment strategy that deserves further investigation.

Clinical trial identification


Editorial acknowledgement

Medical writing support was provided by Lin Dong (Hengrui Pharmaceuticals).

Legal entity responsible for the study

Jiangsu Hengrui Pharmaceuticals Co., Ltd.


Jiangsu Hengrui Pharmaceuticals Co., Ltd.


H. Duan: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.